🔴 UroGen Pharma is trading 10% down after cutting 2026 JELMYTO revenue outlook

UroGen Pharma is trading 10.37% down at $25.76 as investors continue reacting to its November 4 earnings and reduced 2026 JELMYTO outlook.

• 2026 JELMYTO revenue guidance was cut to approximately $90 million from $97 million–$101 million, citing a CMS adjustment and competitive clinical-trial enrollment.
• ZUSDURI revenue grew 35% sequentially to $68 million.
• The outlook change appears to be the clearest company-specific negative catalyst; broader market weakness may also weigh on shares.